PES1 reduces CD8 + T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma

• Published in: Journal of biomedical science Vol. 30; no. 1; p. 20
• Main Authors: Ma, Ning, Hua, Rong, Yang, Yang, Liu, Zhi-Chao, Pan, Jie, Yu, Bo-Yao, Sun, Yi-Feng, Xie, Dong, Wang, Yan, Li, Zhi-Gang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 23.03.2023; BioMed Central; BMC
• Subjects: Analysis; Animals; Antibodies; Biosynthesis; Breast cancer; Cancer; Cancer therapies; CD8 antigen; CD8+ cytotoxic T lymphocytes; CD8-Positive T-Lymphocytes; Cell growth; Cells; Chemotherapy; Cloning; Esophageal cancer; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - genetics; Esophageal Squamous Cell Carcinoma - genetics; Esophageal Squamous Cell Carcinoma - therapy; Gene sequencing; IL15; ILF3; Immune checkpoint inhibitors; Immunohistochemistry; Immunoprecipitation; Immunosurveillance; Immunotherapy; Infiltration; Inoculation; Interleukin 15; Interleukin-15 - pharmacology; Interleukin-15 - therapeutic use; Lymphocytes; Lymphocytes T; Mass spectrometry; Mass spectroscopy; Medical prognosis; Melanoma; Metastases; Mice; mRNA; Nuclear Factor 90 Proteins - metabolism; PD-1; Penicillin; PES1; Proteins; Ribonucleic acid; RNA; RNA sequencing; RNA-Binding Proteins - metabolism; Squamous cell carcinoma; T cells; Therapy; Tumor Microenvironment; Tumors; Western blotting; China; CD8+ cytotoxic T lymphocytes; ILF3; IL15; PD-1; PES1
• ISSN: 1423-0127; 1021-7770; 1423-0127
• DOI: 10.1186/s12929-023-00912-8

Although immune checkpoint blockade (ICB) therapy has brought survival benefits to patients with specific cancer types, most of cancer patients remain refractory to the ICB therapy, which is largely attributed to the immunosuppressive tumor microenvironment. Thereby, it is urgent to profile key molecules and signal pathways responsible for modification of tumor microenvironment. Multiple databases of esophageal squamous cell carcinoma (ESCC) were integratively analyzed to screen candidate genes responsible for infiltration of CD8 T cells. Expression of pescadillo ribosomal biogenesis factor 1 (PES1) in clinical ESCC samples was examined by qRT-PCR, western blotting, and immunohistochemistry. The mechanisms of PES1 were investigated via RNA sequencing and mass spectrometry followed by immunoprecipitation and proximity ligation assay. The clinical and therapeutic significance of PES1 in ESCC was comprehensively investigated using ESCC cells and mouse model. PES1 was significantly upregulated and correlated with poor prognosis in ESCC patients. PES1 knockdown decreased ESCC cell growth in vitro and in vivo and enhanced the efficacy of ICB therapy in mouse model, which was established through subcutaneous inoculation with ESCC cells. Analyses on RNA sequencing and mass spectrometry suggested that PES1 expression was negatively correlated with IL15 and ILF3 was one of the PES1-associated proteins. It has been known that ILF3 interacts with and stabilizes IL15 mRNA to increase IL15 protein level. Our data further indicated that PES1 interfered with the interaction between ILF3 and IL15 mRNA and impaired ILF3-mediated stabilization of IL15 mRNA, which eventually reduced the protein level of IL15. Interestingly, the inhibitory effect of ICB therapy boosted by PES1 knockdown dramatically antagonized by knockdown of IL15, which suppressed the tumor-infiltrated CD8 T cells in ESCC. Finally, we confirmed the relationships among PES1, IL15, and CD8 T cell infiltration in 10 locally advanced ESCC patients receiving ICB neoadjuvant therapy and demonstrated that ICB therapy would be more effective in those with low expression of PES1. Altogether, our findings herein provided novel insights on biological function and clinical significance of PES1 and suggested that high expression of PES1 could suppress ILF3-IL15 axis-mediated immunosurveillance and promote resistance to ICB through restraining tumor-infiltrated CD8 T cells.